Ampligen / rintatolimod for COVID-19

"According to the clinicaltrials.gov data, this trial is currently recruiting participants. The study was initially published on June 1st 2023 and recently updated on 28th of that same month."

"This trial is restricted to patients between 18 and 60 years of age. Meanwhile, 318 other trials are available for minors, while 1048 clinical studies exist that cater to those over the age of 65."

"Ampligen / rintatolimod received a score of 2 on our internal safety scale since there is only limited evidence to suggest its efficacy and some data indicating that it may be safe."

"This clinical trial is seeking 80 participants, aged 18-60 years old, who have had a previously confirmed positive COVID-19 diagnosis at least 12 weeks earlier. Additionally, individuals must display evidence of fatigue per the 1994 CDC Case Definition for Chronic fatigue syndrome (CFS), score ≥12 on PROMIS® Fatigue- Short Form 4a test and receive an Electrocardiogram with no clinically significant findings as assessed by the Investigator. Those presenting symptoms of coronary insufficiency or any other type of cardiac event may not be eligible to participate in this study."

"Affirmative, the information on clinicaltrials.gov attests that this investigation is actively looking for participants. This endeavour was first published on June 1st 2023 and its last update occurred in late June of the same year. It requires 80 individuals to be recruited across two sites."